

Effect of Tff3 protein deficiency on expression of neurodegeneration-associated genes in hippocampi of aged mice

Anušić, Lucija

Master's thesis / Diplomski rad

2021

Degree Grantor / Ustanova koja je dodijelila akademski / stručni stupanj: **University of Zagreb, Faculty of Science / Sveučilište u Zagrebu, Prirodoslovno-matematički fakultet**

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:217:200779>

Rights / Prava: [In copyright](#)/[Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2024-07-19**



Repository / Repozitorij:

[Repository of the Faculty of Science - University of Zagreb](#)



Sveučilište u Zagrebu
Prirodoslovno-matematički fakultet
Biološki odsjek

Lucija Anušić

**Učinak nedostatka proteina Tff3 na
ekspresiju gena povezanih s
neurodegeneracijom hipokampusa u mišjem
modelu starenja**

Diplomski rad

Zagreb, 2021.

University of Zagreb
Faculty of Science
Department of Biology

Lucija Anušić

**Effect of Tff3 protein deficiency on
expression of neurodegeneration-associated
genes in hippocampi of aged mice**

Master thesis

Zagreb, 2021.

Ovaj rad je izrađen u Laboratoriju za istraživanje neurodegenerativnih bolesti na Zavodu za molekularnu medicinu Instituta Ruđer Bošković u Zagrebu, pod voditeljstvom dr.sc. Mirele Baus Lončar i suvoditeljstvom doc.dr.sc. Sofije Ane Blažević. Rad je predan na ocjenu Biološkom odsjeku Prirodoslovno-matematičkog fakulteta Sveučilišta u Zagrebu radi stjecanja zvanja magistar molekularne biologije.

Htjela bih zahvaliti svojim mentoricama Mireli Baus Lončar i Sofiji Ani Blažević na stručnom vodstvu tijekom pisanja diplomskog rada. Također, zahvaljujem Kate Šešelji i Ivi Bazini na pomoći koju su mi pružile tijekom pokusa te na tome što su mi bile izvor odgovora na sva moja pitanja.

TEMELJNA DOKUMENTACIJSKA KARTICA

Sveučilište u Zagrebu
Prirodoslovno-matematički fakultet
Biološki odsjek

Diplomski rad

Učinak nedostatka proteina Tff3 na ekspresiju gena povezanih s neurodegeneracijom u hipokampusu u mišjem modelu starenja

Lucija Anušić

Rooseveltov trg 6, 10000 Zagreb, Hrvatska

Porast incidencije neurodegenerativnih bolesti odraz je kompleksnih kumulativnih procesa tijekom starenja te one uključuju interakcije brojnih organskih sustava. Smanjena razina Trefoil factor 3 (Tff3) proteina u likvoru Alzheimer pacijenata ukazuje na njegovu moguću ulogu u neurodegenerativnim procesima. Tff3 u gastrointestinalnoj mukozi sudjeluje u apoptozi, migraciji i angiogenezi, dok je njegova uloga u neuralnom tkivu gdje je prisutan još nepoznata. U ovom radu, postavili smo hipotezu da nedostatak proteina Tff3 dovodi do veće sklonosti miševa prema razvoju neurodegenerativnih procesa, koje smo mjerili putem relativne ekspresije gena *Bdnf*, *Epac2*, *Nfl*, *Egfr* i *L1cam*. U ovom radu korišteni su miševi stari dvije godine genotipa Tff3-/- C57Bl6/NCrl te odgovarajuće Wt kontrole. Naši rezultati pokazali su da nedostatak Tff3 proteina ne utječe na ekspresiju promatranih gena uključenih u neurodegenerativne procese.

(35 stranica, 14 slika, 7 tablica, 95 literaturnih navoda, jezik izvornika: engleski)

Rad je pohranjen u Središnjoj biološkoj knjižnici

Ključne riječi: *Bdnf*, *Egfr*, *Epac2*, hipokampus, *L1cam*, neurogeneza, neuroplastičnost, *Nfl*

Voditelj: dr.sc. Mirela Baus Lončar

Suvoditelj: doc.dr.sc. Sofia Ana Blažević

Ocjenitelji:

doc.dr.sc. Sofia Ana Blažević

izv.prof.dr.sc. Inga Urlić

doc.dr.sc. Marin Ježić

Rad prihvaćen: 15.9.2021.

This thesis was created in the Laboratory for Neurodegenerative Disease Research at the Division of Molecular Medicine at the Ruđer Bošković Institute in Zagreb, under the supervision of Mirela Baus Lončar, PhD and the co-supervision of Sofia Ana Blažević, PhD, Assist Prof. The thesis is submitted for grading to the Department of Biology at the Faculty of Science, University of Zagreb, with the aim of obtaining a Master's degree in molecular biology.

I would like to thank my mentors Mirela Baus Lončar and Sofia Ana Blažević for guidance during the writing of the thesis. Also, I would like to thank Kate Šešelja and Iva Bazina for the help given during the experiments and for being the sources of answers to all of my questions.

BASIC DOCUMENTATION CARD

University of Zagreb
Faculty of Science
Department of Biology

Master Thesis

Effect of Tff3 protein deficiency on expression of neurodegeneration-associated genes in hippocampi of aged mice

Lucija Anušić

Rooseveltov trg 6, 10000 Zagreb, Hrvatska

The increase in the incidence of neurodegenerative diseases is a reflection of complex cumulative processes during aging which involve the interactions of numerous organ systems. Decreased levels of Trefoil factor 3 (Tff3) protein in the cerebrospinal fluid of patients with Alzheimer's disease indicate its possible role in neurodegenerative processes. Tff3 is involved in a variety of processes such as healing of mucosal surfaces in the gastrointestinal tract and apoptosis, migration, and angiogenesis, while its role in neural tissue is still unknown. In this paper, we hypothesized that Tff3 protein deficiency leads to a greater affinity of mice for the development of neurodegenerative processes, which we measured through the relative expression of the following genes: brain-derived neurotrophic factor (*Bdnf*), exchange protein directly activated by cAMP 2 (*Epac2*), epidermal growth factor receptor (*Egfr*), neurofilament light protein (*Nfl*) and L1 cell adhesion molecule (*L1cam*). Two - year - old mice of the *Tff3*^{-/-} C57Bl6/NCrl genotype and appropriate Wt controls were used in this study. Our results showed that Tff3 protein deficiency does not affect the expression of the observed genes involved in neurodegenerative processes.

(35 pages, 14 figures, 7 tables, 95 references, original in: English)

Thesis is deposited in Central Biological Library.

Keywords: *Bdnf*, *Egfr*, *Epac2*, hippocampus, *L1cam*, neurogenesis, neuroplasticity, *Nfl*

Supervisor: Mirela Baus Lončar, PhD

Co-supervisor: Sofia Ana Blažević, PhD, Assist Prof

Reviewers:

Sofia Ana Blažević, PhD, Asst. Prof.

Inga Urlič, PhD, Assoc. Prof.

Marin Ježić, PhD, Asst. Prof.

Thesis accepted: 15/9/2021

LIST OF ABBREVIATIONS

AD - Alzheimer's disease
B2M - beta-2 microglobulin
Bdnf - brain-derived neurotrophic factor
CA1-CA3 - *cornu ammonis*
CAM - cell adhesion molecule
cAMP-GEF-ii - camp-guanine activated exchange factor
CNS - central nervous system
CSF - cerebrospinal fluid
DG - dentate gyrus
Egf - epidermal growth factor
Egfr - epidermal growth factor receptor
Epac2 - exchange protein directly activated by cAMP 2
GAPDH - glyceraldehyde 3-phosphate dehydrogenase
GI - gastrointestinal
GOI – gene of interest
HDAC2 - histone deacetylase 2
ITF - intestinal trefoil factor
L1cam - L1 cell adhesion molecule
LTD - long-term depression
LTP - long-term potentiation
MRI - magnetic resonance imaging
NDD - neurodegenerative disease
Nfl - neurofilament light protein
NFT - intracellular neurofibrillary tangles
NSC - neural stem cell
qPCR – quantitative polymerase chain reaction
RT – reverse transcription
SGZ - subgranular zone
TFF3 - trefoil factor 3 peptide

TABLE OF CONTENTS

1. INTRODUCTION	1
1.1. Trefoil factor 3 (TFF3)	1
1.2. The hippocampus, adult neurogenesis, and neuroplasticity	3
1.2.1. Hippocampal structure and function	3
1.2.2. Neuroplasticity and adult neurogenesis	6
1.3. Neurodegeneration-related genes	8
1.3.1. Brain-derived neurotrophic factor (Bdnf)	8
1.3.2. Epidermal growth factor receptor (Egfr)	9
1.3.3. Exchange protein directly activated by cAMP 2 (Epac2)	9
1.3.4. L1 cell adhesion molecule (L1cam).....	10
1.3.5. Neurofilament light protein (Nfl)	10
1.4. Aged mice model and hypothesis	11
2. STUDY AIM	12
3. MATERIAL AND METHODS	13
3.1. Primer optimization	13
3.2. Animal experiments	14
3.2.1. Tissue isolation.....	14
3.2.2. RNA isolation and reverse transcription (RT)	15
3.2.3. Quantitative polymerase chain reaction (qPCR)	15
3.2.4. Polyacrylamide gel electrophoresis	16
3.2.5. Relative quantification of gene expression	17
4. RESULTS	18
5. DISCUSSION	22
6. CONCLUSIONS	26
REFERENCES	27

1. INTRODUCTION

1.1. Trefoil factor 3 (TFF3)

The trefoil factor 3 (TFF3) peptide, also known as the intestinal trefoil factor (ITF), was discovered in humans in 1993 after the discovery of its homolog in rats in 1991 (Podolsky et al., 1993). TFF3 belongs to the trefoil factor (TFF) family, including TFF1 and TFF2 (Hoffman et al., 2001). Accepted nomenclature marks human proteins as TFFs and genes as *TFF 1-3* while rodent proteins are Tffs and genes *Tff 1-3*. TFF genes are located on the short arm of chromosome 21 in humans (Gött et al., 1996) and on chromosome 17 in mice (Ribieras et al., 1998). The TFF peptides contain one or two trefoil domains as their functional units. The domain consists of a sequence of 38/39 amino residues in which six cysteines form three intramolecular disulfide bonds (Thim, 1989; Thim, 1997). These bonds render the peptides resistant to proteolytic cleavage (Thim, 1994).

Human studies indicate the mucous epithelial cells, known as goblet cells, to be the main site of TFF3 production (Hoffmann et al., 2001; Hoffmann et al., 2002). A large amount of TFF3 can be found secreted in human intestinal goblet cells, the colon, salivary glands, conjunctival goblet cells, the uterus, and the cells of the respiratory tract (Thim, 1997). In all of these sites, TFF3 is co-secreted with mucin (Hoffmann et al., 2002). Also, it can be found in a variety of bodily fluids like breast milk, urine, sputum, cerebrospinal fluid, gastric juice, and tears, as well as in organs like the lungs, the pancreas, the mammary gland, the inner ear, lymphoid tissue, and the brain (Bernstein et al., 2015). Tff3 is also found expressed in the central nervous system (CNS) (Fu et al., 2014). Tff3 has an essential role in the healing of intestinal mucosa (Mashimo et al., 1996). It is also necessary for the promotion of cellular migration, apoptosis, and angiogenesis (Bossenmeyer-Pourié et al., 2002; Lubka et al., 2009; Mashimo et al., 1996; May et al., 1997). The Tff proteins on the epithelial surface operate in three principal ways: by the regulation of apoptosis (Lubka et al., 2019), by their involvement in migration processes, and by being part of mucous gels (Hoffmann et al., 2001). Tff3's expression is upregulated in cases of intestinal inflammation (Cook et al., 1999) and following a wound in the mucosa of the gastrointestinal (GI) tract (Lefebvre et al., 1996). Even though all peptides from the Tff family are able to promote cell migration, only

Tff3 is of paramount importance in the process of mucosal restitution (Mashimo et al., 1996; Podolsky, 1997).

There is an abundance of *TFF3* mRNA in most areas of the brain in both rodent and humans. More precisely, the transcripts can be found in the supraoptic and paraventricular nuclei of the rat and human hypothalamus (Bernstein et al., 2015; Probst et al., 1995; Probst et al., 1996), in the human cerebrospinal fluid (CSF) from the third ventricle, in the rat amygdala and the magnocellular neurons of the hypothalamus (Schwarzberg et al., 1999), as well as in the hippocampi and the cerebellum of mice (Hinz et al., 2004). Moreover, Tff3 is found and synthesized in oxytocinergic neurons of the hypothalamus which innervate the spinal cord, the pontine tegmentum, and the brain stem (Griepentrog et al., 2000; Jagla et al., 2000; Schwarzberg et al., 1999). Tff3 is probably co-accumulated with oxytocin in the neural lobe of the pituitary (Griepentrog et al., 2000; Hinz et al., 2004) and co-secreted with it into the bloodstream as a reaction to external stimuli (Hoffmann et al., 2001). Bernstein et al. systematically examined *TFF3* expression in the human brain and found that the TFF3 protein is present in neurons of various human brain regions. This wide cerebral distribution suggests that TFF3 has an important physiological role in the CNS (Bernstein et al., 2015). Nevertheless, this is still a novel research field and the protein's role has yet to be determined.

Altered *TFF3* expression in peripheral tissues has been associated with neurological disorders, such as schizophrenia (Gardiner et al., 2013) and Parkinson's disease (Zou et al., 2018). Moreover, pharmacological administration of TFF3 has been reported to facilitate learning, object recognition, and retention of memory (Schwarzberg et al., 1999), as well as evoke antidepressant-like behavior (Li et al., 2015; Shi et al., 2012). TFF3 was identified as a marker of neurodegeneration in amyloid-positive individuals expressed independently from tau and p-tau. Its low expression in the CSF strongly correlated with brain atrophy, ventricular expansion, and hippocampal atrophy (Paterson et al., 2014). As already mentioned, it has been shown that Tff3 is expressed during neurodevelopment (Belovari et al., 2015). Having a mitogenic effect, Tff3 has a role in postnatal cerebellar development where it is involved in the differentiation program of cells in the granule cell layer of the cerebellum (Hinz et al., 2004). Given the known Tff3 mechanism of action in intestinal epithelial cells where it acts as a motogen (Baus-Loncar and Giraud, 2005), we hypothesized that Tff3 could be exerting its role in the hippocampus by participating in similar cellular processes (cell migration, adhesion, mitogenic effect).

1.2. The hippocampus, adult neurogenesis, and neuroplasticity

1.2.1. Hippocampal structure and function

In 1957, the strange case of patient H.M. ignited interest in the neuroscientific community. The patient's hippocampus had been surgically removed as part of a treatment plan for epilepsy and was later found to be unable to produce any new memories (Scoville and Milner 1957). Following this discovery, the hippocampus was later found to be crucial in the processes of learning, spatial navigation, and the regulation of emotions. It is also the main site of memory processing, consolidation, and retrieval (Bartsch and Wulff, 2015; Tatu, 2014). The hippocampus is both structurally and functionally a heterogeneous structure. This heterogeneity of function is a reflection of the differential connectivity of its subregions (Moser and Moser, 1998).

Together with the cerebral cortex, the hippocampus is the brain area most affected in neurodegenerative diseases (NDDs), with regards to cognitive decline impairment (Arushanyan and Beier, 2008). Magnetic resonance imaging (MRI) studies of Alzheimer's disease (AD) patients have shown a strong connection between hippocampal structural change and its lesions (Wang et al., 2012), with Alzheimer's disease (Arushanyan and Beier, 2008; Paterson et al., 2014). Therefore, structural changes in the hippocampus are used as a biomarker for the diagnosis of pathological states (Lindberg et al., 2012).

The hippocampus is functionally divided into different subregions and subnetworks (Strange et al., 2014), with the main ones being the dentate gyrus (DG), the subiculum, and the *cornu ammonis* fields (CA1-CA3) (Schultz and Engelhardt, 2014). There are 3 layers of organization of the CA1-CA3 subfields' pyramidal cells: the stratum lucidum, the stratum radiatum, and the stratum lacunosum-moleculare (Bartsch and Wulff, 2015). In the human brain, the hippocampus is positioned ventrally in the medial temporal lobe (Figure 1) (Strange et al., 2014) and is shaped in the form of a crescent moon (Schultz and Engelhardt, 2014). In rodents, however, the hippocampus is situated right beneath the neocortex and is shaped like a cashew nut (Figure 2) (Bartsch and Wulff, 2015). The longitudinal axis of the human hippocampus has an anterior-posterior orientation which corresponds to the ventral-dorsal orientation in rodents. The ventral hippocampus is associated with the regulation of emotion, while the dorsal hippocampus has a role in spatial memory and cognition (Moser and Moser, 1998). This finding may be further corroborated by the fact that the NMDA and AMPA receptor subunits are differentially expressed

in the dorsal and ventral rat hippocampi. As the center of an important brain network, it is connected to many other cortical and subcortical regions such as the neocortical association areas (Bartsch and Wulff, 2015).




Figure 1. A) The hippocampus and entorhinal cortex in the human brain, B) The human hippocampus and its anterior-posterior orientation (Strange et al., 2014)




Figure 2. A) The hippocampus and entorhinal cortex in the rat brain, B) The rodent hippocampus and its ventral-dorsal orientation (Strange et al., 2014)

All mammalian brains have a hippocampus that has what is essentially the same neuronal circuitry, making it an evolutionary old cerebral structure (Strange et al., 2014). Even though there are multiple interconnected pathways extant in the longitudinal axis of the hippocampus, this brain structure is anatomically connected primarily through a „trisynaptic loop“ (Figure 3). Within this loop, the entorhinal cortex (EC) sends the main cortical input to the dentate gyrus (DG) via the perforant path consisting of layer II neurons and to CA1 via layer III neurons. The DG then signals to the CA3 region through the mossy fiber pathway. The next signal in the loop projects from the CA3 to the CA1 region via the Schaffer Collaterals. The pyramidal cells of the CA1 region then connect back to the EC (Knierim, 2015). Newer studies show that there are also projections coming from the EC to the CA3 and CA1 and signaling from CA3 back to DG and other CA3 neurons. Furthermore, the CA1 projects to the amygdala, the subiculum, and the prefrontal cortex. The subiculum projects back to polymodal association cortices in the neocortex (Schultz and Engelhardt, 2014). The CA3 hippocampal subfield and the DG have an essential role in memory encoding and early memory retrieval, while the CA1 hippocampal subfield is important in memory consolidation and late retrieval of autobiographical memory (Bartsch and Wulff, 2014).




Figure 3. The „trisynaptic loop“ as the primary neural circuit in information processing in the hippocampus – A) Structure of the loop, B) Pathways in the loop (Bartsch and Wulff, 2015)




Figure 4. The “trisynaptic loop” shown inside the section of the human hippocampus (Schultz and Engelhardt, 2014)

1.2.2. Neuroplasticity and adult neurogenesis

The hippocampus shows a high degree of neuroplasticity, which includes structural dendritic and axonal modifications, changes in membrane excitability, synapse numbers, synapse connectivity, and the formation of new neurons (neurogenesis) (Leuner and Gould, 2010). Neuroplasticity is the ability to reorganize neuronal structure and function in response to internal and external stimuli and can be most appropriately seen in hippocampal neurons. This ability is one of the properties needed for memory formation (Spalding et al., 2013). Plasticity can occur at the presynaptic level by the regulation of neurotransmitter levels or postsynaptically by the modification of neurotransmitter receptors (Lea et al., 2017). Higher levels of neuroplasticity seen on the scale of neuronal networks are made possible by the basic levels of neuroplasticity that occur via molecular cascades. Protein kinases, phosphatases, and proteases all have important molecular roles in the regulation of synaptic plasticity, which is in turn reliant on the timely phosphorylation and dephosphorylation of synaptic proteins (Gulyaeva, 2017). Moreover, increased expression of plasticity-related genes such as *Bdnf*, *CREB*, as well as *AMPA* and *NMDA* receptors can lead to higher levels of neuroplasticity (Bartsch and Wulff, 2015).

The results of neuroplasticity can be seen in modified cerebral structure, brain activity and behavior. The processes of long-term potentiation (LTP) and long-term depression (LTD) are indispensable when discussing hippocampal neuroplasticity (Schultz and Engelhardt, 2015). Long-term potentiation is induced by a short-lived high-frequency stimulation of synapses (Baltaci et al., 2019). Characterized by the electrical activity of synaptic transmissions (Arushanyan and Beier, 2008) and an increase in synaptic response (Baltaci et al., 2019), long-term potentiation is the essential mechanism underlying learning and memory (Nicoll, 2017). There are two types of hippocampal LTP. The first type of LTP is postsynaptic, requires NMDA receptors, and involves excitatory synapses between the Schaffer collateral terminals and the CA1 subregion. The second type is presynaptic, does not require NMDA receptors, includes mossy fibers, and occurs between the DG and the CA3 pyramidal cells (Baltaci et al., 2019; Nicoll, 2017).

Adult neurogenesis is the main process required for neural plasticity and occurs in the olfactory bulb, the subventricular zone of the forebrain and the dentate gyrus of the mammalian hippocampus (Bartsch and Wulff, 2015, Spalding et al., 2013). The process of adult neurogenesis is shaped by a plethora of molecular stimuli, including various transcription and growth factors, neurotrophins, and microglia 1 inflammatory cytokines (Goncalves, 2016). Newborn adult neurons in the DG are needed for context-dependent memory, learning, and differentiation of similar memories (pattern separation) (Clelland et al., 2009). The dentate gyrus consists of 3 cell layers named the molecular, the polymorphic, and the granular (Amaral et al., 2007). Most of the DG is made of glutamatergic granular cells and it is thought that adult neurogenesis in humans is restricted to its subgranular zone (SGZ) (Bartsch and Wulff, 2015). The SGZ of the dentate gyrus is the place in the adult mammalian brain that contains neural stem cells (NSC) and allows their proliferation. The NSCs differentiate into intermediate progenitor cells (IPCs), which can then turn into immature neurons. The immature neurons can then finally differentiate into adult-born dentate granule neurons. In order to become adult neurons and part of the hippocampus, the dentate granule neurons go through several developmental stages (Figure 5) (Goncalves et al., 2016).




Figure 5. Adult hippocampal neurogenesis (Gonçalves et al., 2016)

Moreover, impairments in adult neurogenesis have been associated with neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's disease (Gonçalves et al., 2016). In the hippocampi of AD patients, new neurons are found in low numbers (Moreno-Jiménez et al., 2019). Neuroplastic processes and mechanisms are more vulnerable in aged individuals, and neurogenesis in the dentate gyrus decreases with age. Even though beneficial in some aspects, neuroplasticity at the cellular level might be the cause of a higher dose of hippocampal vulnerability and, therefore, implicated in the formation of neurodegenerative diseases. In the early stages of AD, hippocampal vulnerability leads to destructive pathological changes in extracellular amyloid-beta protein and intraneuronal neurofibrillary tangles formation (Bartsch and Wulff, 2015). Advanced age is recognized as the number one cause of NDDs' onset in humans (Hou et al., 2019). Furthermore, neurogenesis levels decrease as a function of age in both humans and rodents (Gonçalves et al., 2016).

1.3. Neurodegeneration-related genes

1.3.1. Brain-derived neurotrophic factor (Bdnf)

Bdnf is a neurotrophic factor essential for neuronal survival, axonal growth, and synaptic plasticity, all of which are processes involved in learning and memory (Autry et al., 2012). Bdnf molecules in the hippocampus are localized at the presynaptic terminals of neurons, to where they are transported along the axons via large dense core vesicles (Leal et al., 2017). Bdnf controls excitatory and inhibitory synaptic transmission in the adult brain. Being a neurotrophin, it promotes downstream signaling through TrkB which leads to enhanced long-term potentiation of the hippocampal excitatory glutamatergic synapses (Miranda et al., 2019; Panja and Bramham,

2014). The activation of glutamatergic synapses depends on extracellular calcium levels (Leal et al., 2017). The Bdnf-TrkB complex induces mTORC1 activation and thereby regulates dendritic protein synthesis. Additionally, the ERK/MAPK cascade is set off by Bdnf and leads to the synthesis of translation-related proteins important for LTP (Panja and Bramham, 2014). However, when acting through p75, Bdnf produces long-term depression (Tanila, 2017).

1.3.2. Epidermal growth factor receptor (Egfr)

Egfr has so far been studied to a great extent. In adult rats, Egfr's presence has been described in layers IV and V of cerebral cortical neurons. Furthermore, the receptor has been found expressed in the subgranular zone of the adult hippocampus, which is the site of adult neurogenesis (Wong and Guillaud, 2004). Egfr ligands control the processes of maturation, cell survival, cellular proliferation, differentiation, and neurogenesis in both the developing and adult brain (Wang et al., 2012 8). Egfr regulates the proliferation of the following precursor cells: neural stem cells, neural progenitor cells, and glial progenitor cells (Wong and Guillaud, 2004). In the rat hippocampus, the activation of Egfr by the epidermal growth factor (Egf) has been proven to increase LTP in Schaffer/commissural-CA1 synapses *in vitro*, and to induce LTP in the perforate-path dentate granule cells *in vivo*, therefore having a role in synaptic plasticity (Yamada et al., 1997).

1.3.3. Exchange protein directly activated by cAMP 2 (Epac2)

Epac2, also known as the camp-guanine activated exchange factor (cAMP-GEF-ii) for the Rap and Ras-like GTPases, modulates neuronal excitability and promotes neurotransmitter release in glutamatergic neurons (Grandoch et al., 2010). cAMP binds to the two cAMP-binding domains on Epac2 and thereby improves the catalytic activity of Epac towards its GTP-ase target Rap (Jones et al., 2019). Having been found in great amounts in the mammalian cortex and the hippocampus, it was concluded that Epac2 promotes neurotransmission in the hippocampus (Fernandes et al., 2015). *Epac2* expression has so far been described in adrenal glands, the brain, the lungs, and vasculature (Grandoch et al., 2010; Zhang et al., 2018) and is especially highly expressed in the presynaptic terminals of axons (Fernandes et al., 2015). It is of note that *Epac2* mRNA expression

pattern is dependent on the developmental stage the tissue is in and is upregulated in adult brain tissue, as opposed to Epac1 that is active in fetal stages (Murray et al., 2008). Some of the processes that include Epac2 and mediation by cAMP are calcium handling, cardiac muscle contraction, cell proliferation and differentiation, apoptosis and inflammation, chromosomal integrity (Grandoch et al., 2010). Epac2 exerts its function on the ERK1/2 pathway, which leads to increased cell survival (Zhang et al., 2018). Hippocampus-related processes regulated by Epac2 and mediated by cAMP are neuronal plasticity (Fernandes et al., 2015), working and reference memory, and synaptogenesis (Jones et al., 2019).

1.3.4. L1 cell adhesion molecule (L1cam)

L1cam is a protein from the family of neural cell adhesion molecules (CAMs) which have an important role in mediating the interaction between the cell and its environment. CAMs have a role in cell migration, axonal and dendritic projection, and synaptic targeting (Fransen et al., 1997; Schmid and Maness, 2008). Neurons and glial cells in both the central and the peripheral nervous system (PNS) express L1cam on their surfaces during embryonic and postembryonic stages of development (Hortsch, 1996). Even though L1cam is important in the development of the brain because its activation of the ERK/MAPK pathway leads to cell migration, this signaling can also promote tumor progression (Schmid and Maness, 2008). Interactions of L1 peptides with other proteins in the brain lead to a calcium cascade activation resulting in the induction of neurite outgrowth. Additionally, L1cam molecules have been proposed to have a role in LTP in the hippocampus (Hortsch, 1996). L1cam is also responsible for the inhibition of a gene transcription blocker histone deacetylase 2 (HDAC2). HDAC2 inhibits the expression of synaptic plasticity-related genes and prevents normal cognitive functioning (Hu et al., 2020).

1.3.5. Neurofilament light protein (Nfl)

Nfl is one of the domains of neurofilaments (NFs) and has a role in neuronal structural stability. *Nfl* is expressed only in mature neurons in the CNS and the PNS (Gentil et al., 2012). It is an AD biomarker that detects neuroaxonal damage and is quite sensitive to neurodegenerative progression and changes throughout the stages of the disease (Hampel et al., 2018; Mattsson et al., 2019). It is usually found in the CSF, but it is as of recently possible to detect it in blood samples

as well (Hampel et al., 2018). Low levels of Nfls are expected in physiological conditions, while high levels tend to be present in aged individuals (Gaetani et al., 2019).

1.4. Aged mice model and hypothesis

In our study, we used an aged mice model to investigate the effect of Tff3 deficiency on the expression of genes involved in adult neurogenesis that are subsequently associated with the pathophysiology of AD in the murine hippocampus. Aged mice are susceptible to many health problems, some of them being neurodegenerative diseases such as Alzheimer's disease (AD). These mice are also more prone to major changes in physiology and behavior and may form lesions characteristic of aging (www.criver.com).

We monitored the expression of brain-derived neurotrophic factor (*Bdnf*), epidermal growth factor receptor (*Egfr*), exchange protein directly activated by cAMP 2 (*Epac2*), L1 cell adhesion molecule (*L1cam*), and neurofilament light protein (*Nfl*). We hypothesized that the depletion of the *Tff3* gene would lead to significantly altered levels of expression of analyzed genes in aged mice. Their altered levels would signify a potentially important role of Tff3 in neurogenesis processes and AD pathology and could be further explored as a potential biomarker of neurodegeneration.

2. STUDY AIM

The general aim of this study was to examine the role of the Tff3 protein deficiency on the expression of neurodegeneration-associated genes (*Bdnf*, *Epac2*, *Egfr*, *L1cam*, and *Nfl*) in the aging process. According to the described Tff3 protein function in apoptosis and inflammation, we have postulated that Tff3 deficiency would have an impact on the level of expression of neurodegeneration-relevant genes.

3. MATERIAL AND METHODS

3.1. Primer optimization

In order to verify the optimal conditions for adequate specificity and primer binding, we carried out primer optimization for five genes of interest (GOI) and two reference genes. The genes of interest investigated were the brain-derived neurotrophic factor (*Bdnf*), exchange protein directly activated by cAMP 2 (*Epac2*), epidermal growth factor receptor (*Egfr*), neurofilament light protein (*Nfl*), and L1 cell adhesion molecule (*L1cam*). The reference genes used were glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) and beta-2 microglobulin (*B2M*).

One pair of primers was tested out for each gene (Table 1). The primers were created with the Primer Quest Tool software. The optimal temperatures for each primer were searched for within the binding range of temperatures for primers: 57°C – 65°C. The MgCl₂ concentrations used were: 2.5mM, 3mM and 3.5mM. SYBR Green was used as the coloring agent in the qPCR reaction. SYBR Green is a stain that binds to all double-stranded nucleic acids, including primer dimers. To be sure that we would get only one specific product in the PCR reaction (double-stranded DNA), primer optimization was necessary. We confirmed the qPCR reaction primer binding specificity upon the creation of a melting curve and polyacrylamide gel electrophoresis (PAGE). The primers whose melting curves had only one significantly more prominent peak were chosen for the experimental part of the study because they indicated only one major product present at the end of the reaction.

We analyzed the efficacy of the qPCR reaction. There were three dilutions made for which the Ct values were measured. Ct or cycle threshold is a value indicating the starting amount of nucleic acids in the sample. The obtained Ct values from the reactions were used by the StepOnePlus™ software to calculate the efficacy of the reaction. The software generates standard curves for each set of primers by plotting the log value of nucleic acids (the primary concentrations of samples used) versus Ct values from the PCR reactions. PCR efficacies for each gene of interest were then calculated from the slope of the standard curves by using the equation:

$$E = 10^{-1(\text{line slope})}; \%E = E - 1(\times 100)$$

Table 1. Primers and optimised annealing temperatures

gene	primer	primer sequence	annealing temperature/°C
<i>Epac2</i>	<i>Epac2</i> F	TGTCTCCAGTCCACAATCTTTC	58
	<i>Epac2</i> R	GGATGTGTCTCTTTGCTCATTCT	
<i>Egfr</i>	<i>Egfr</i> F	ACAGCGCTACCTTGTTATCC	59
	<i>Egfr</i> R	CATCCTCCATGTCCTCTTCATC	
<i>Bdnf</i>	<i>Bdnf</i> F	CAAGAGTCCCGTCTGTACTTTAC	59
	<i>Bdnf</i> R	GACTAGGGAAATGGGCTTAACA	
<i>Nfl</i>	<i>Nfl</i> F	GCTCTTTCCAGCCTACTATAC	59
	<i>Nfl</i> R	TTCTCCTTCTCCTCCTCTTCT	
<i>Llcam</i>	<i>Llcam</i> F	AGCACAGCAAGAGGCATATC	65
	<i>Llcam</i> R	CCACATGGTAAGAGCTGTAAGG	

3.2. Animal experiments

3.2.1. Tissue isolation

The tissue samples I used were murine hippocampi of male, 2-year-old, *Tff3*^{-/-}//C57Bl6/NCrl and Wt controls (C57Bl6/NCrl). The mice were bred at the Facility for laboratory animals of the Ruđer Bošković Institute from a mouse strain originally purchased from Charles River Laboratories. The mice were kept in small mice cages (dimensions: 235x135x130 mm) under the following conditions: 22°C temperature, 12 hour light/dark cycle and 58% humidity. The mice were fed normal chow (Mucedola) and given water *ad libitum*. In total there were 16 samples, 8 Wt controls and 8 *Tff3*^{-/-} mice. The experiment was approved by the Bioethical committee of the Ruđer Bošković Institute and the Ethics Committee of the Croatian Ministry of Agriculture on July 5th 2019. The mice were anesthetised using isoflurane, sacrificed by cervical dislocation and hippocampal tissue was isolated by certified scientists and stored on ice. All hippocampal tissue from the samples was homogenized.

3.2.2. RNA isolation and reverse transcription (RT)

The total RNA of the sample (NucleoSpin RNA; Applied Biosystems) was isolated according to the manufacturer's instructions. The RNA was purified (NucleoSpin R; Applied Biosystems) according to the manufacturer's instructions and the total RNA's concentration and purity was measured using the NanoPhotometer® N60. The RNA was reverse transcribed into cDNA (The High Capacity cDNA Reverse Transcription Kit; Applied Biosystems Step One) according to the manufacturer's instructions. The contents of the reaction mix were as shown in Table 2. One sample contained 1.5 µg of RNA. The reaction was carried out in the Veriti 96 Thermal Cycler (Applied Biosystems) under the following conditions: 10min at 25°C, 120 min at 37°C, 5min at 85°C, and at the end stored at 4°C.

Table 2. RT reaction mix for 1 sample

10X RT buffer	4µl
25X dNTP Mix (100Mm)	1.6µL
10X radnom primer	4µL
MultiScribe Reverse Transcriptase (50U/UL)	2µL
RNAse inhibitor	2µL
Nuclease-free H ₂ O	6.4µL

3.2.3. Quantitative polymerase chain reaction (qPCR)

The cDNA of each sample was amplified through a qPCR reaction using the StepOnePlus™ Real-Time PCR System. Each well contained concentrations and volumes according to Table 3 and 4. The reverse transcription and PCR steps were conducted separately, which allowed for optimized conditions to be used for each reaction (www.thermofisher.com). The experimental samples were done in triplicates, while the negative controls in duplicates. The dye we used for the detection was SYBR Green. There were 40 amplification cycles in each

reaction. The conditions were as follows: 3 min of preparatory denaturation at 95 °C, 1min of denaturation at 95 °C, 30 seconds of annealing at according primer annealing temperatures (Table 1), 30 seconds of DNA elongation at 72°C. The machine measured the fluorescence levels during the elongation phase of the reaction.

Table 3. qPCR mix components

H2O	MgCl ₂ (25 mM)	dNTP (5mM each)	M- buffer*	Taq ₂	SYBR green (1000x)	ROX 100x reference dye	Total volume of mastermix
15.75µL	2.5µL						
15.25µL	3µL	1µL	2.5µL	1µL	0.0025µL	0.25µL	23µL
14.75µL	3.5µL						

*M-puffer: 800mM KCl, 100 mM Tris-HCl; pH=8,3

Table 4. Well contents for qPCR

	volume	concentration
mastermix	23µL	*
primer	1µL	5µM
cDNA	1µL	0.04µg/µL

*mastermix components are shown in Table 3

3.2.4. Polyacrylamide gel electrophoresis

The samples were ran on several polyacrylamide gels made as indicated in Table 5. The ratio of the DNA: loading buffer (10X bromophenol-blue) was 5:1. The electrophoresis conditions were: 100V, 400mA during 3h. We treated the gels with ethidium bromide and inspected them under UV light.

Table 5. 12%-gel components for PAGE

*mix AA:BIS	5.85 mL
10XTBE	4.875 mL
H2O	8.775 mL
10% APS	195 µL
TEMED	19.5 µL

*Rotiphorese Gel 40 (19:1)

3.2.5. Relative quantification of gene expression

I used the REST-MCS (c) version 2 (Relative Expression Software Tool – Multiple Condition Solver) software for the calculation of the relative expression of genes in real-time PCR. The used statistical model was the *Pair Wise Fixed Reallocation Randomisation Test* (c). The reference genes used were: *GAPDH* and *B2M*. The genes of interest were: *Bdnf*, *Egfr*, *Epac2*, *L1cam*, and *Nfl*. The expression of the GOI and reference genes was measured and then compared between the hippocampi of healthy Wt males and the males who were knockouts (KO) for the *Tff3* gene. The equation used by the software is shown in Figure 1.

$$R = \frac{(E_{\text{target}})^{\Delta C_{\text{Ptarget}} (\text{MEAN control} - \text{MEAN sample})}}{(E_{\text{ref}})^{\Delta C_{\text{Pref}} (\text{MEAN control} - \text{MEAN sample})}}$$

Figure 1. Equation for the calculation of relative gene of interest expression

4. RESULTS

In this study, I first optimized the qPCR conditions for primers in order to be sure of the experiment's efficacy and specificity. The best conditions (Table 1) for primer performance were determined by analyzing PCR reactions at different annealing temperatures, melting curve analysis and final PAGE electrophoreses (Figure 1-2) check-up. It was important to obtain only one band for each gene of interest on the electrophoresis gel which signaled the correct specific bindings of the primers. The bands on the gels indicated the chosen primers to be appropriate for the experiment.

Table 1. Obtained optimal conditions for primers

Primers	Epac2	Egfr	BDNF	Nfl	L1cam
optimal temperature	58°C	59°C	59°C	59°C	65°C
optimal MgCl ₂ concentration	3.5mM	3.5mM	2.5mM	3.5mM	3mM
Efficacy	103%	112%	112%	91%	108.21%




Figure 1. Gel electrophoresis – Epac2, BDNF, EGFR, Nfl




Figure 2. Gel electrophoresis – L1cam

Standard curves generated for each set of primers are presented in Figure 3-7. In ideal conditions in the qPCR reaction, the amount of the amplified DNA and the subsequent intensity of the SYBR GREEN dye should double each cycle, giving the efficacy of 100%. Given that the conditions were not ideal, the range of acceptable efficacy was approximately 95% to 110%. All slope values between -3.9 and -3.0 are acceptable.




Figure 3. Epac2 F/R efficacy – 103%




Figure 4. EGFR F/R efficacy – 112%




Figure 5. BDNF F/R efficacy – 112%




Figure 6. Nfl F/R efficacy - 91%




Figure 7. L1cam F/R efficacy – 108.21%

Using the *Pair Wise Fixed Reallocation Randomisation test* in the aforementioned REST-MCS software, I found no significant difference in expression ratios between the Wt and *Tff3*^{-/-} samples. The expression levels of *Epac2*, *Egfr* and *Bdnf* were found to be slightly increased in *Tff3*^{-/-} mice and the expression levels of *Nfl* and *L1cam* were found to be slightly decreased in *Tff3*^{-/-} mice as presented in Table 2 and Figure 8.

Table 2. Expression ratios and absolute gene regulation of *Epac2*, *Egfr*, *Bdnf*, *Nfl* and *L1cam*

	<i>Epac2</i>	<i>Egfr</i>	<i>Bdnf</i>	<i>Nfl</i>	<i>L1cam</i>
expression ratio	1.061	1.060	1.177	0.882	0.996
gene UP-regulated by the factor	1.061	1.060	1.177		
gene DOWN-regulated by the factor				-1.133	-1.005
absolute gene regulation	1.061	1.06	1.177	0.882	0.996
standard error	0.1977	0.22046	0.33765	0.20789	0.23884
2log (bidirectional)	0.086	0.084	0.236	-0.181	-0.007
2log (standard error)	0.01593	0.01757	0.06754	0.03311	0.00155




Figure 8. GOI expression ratios between *Tff3*^{-/-} and Wt samples (standard errors indicated with standard bars)

5. DISCUSSION

Today, a major global health problem with a big impact on the quality of human life are different neurodegenerative diseases. As the human population is getting older and the individual's lifetime is expanding, cases of neurodegenerative diseases are rising in number (Hou et al., 2019). Thus, there is a need for better diagnostic techniques and new, more efficient therapeutic approaches for neurodegenerative diseases (Paterson et al., 2014; Wang et al., 2012). The most prominent among them is Alzheimer's disease, marked with cognitive decline, dementia, and difficulties in learning (Arushanyan and Beier, 2008; Breijyeh and Karaman, 2020; Gonçalves et al., 2016; Hou et al., 2019). Alzheimer's disease progresses through a reduction of synaptic proteins, neuronal loss, changes in synaptic morphology, and neuroinflammation (Breijyeh and Karaman, 2020). AD patients may possess various morphological changes in their brains such as a) intracellular neurofibrillary tangles (NFTs), which consist of p-tau aggregates; b) senile plaques, which consist of AB amyloid aggregates; or c) degenerated brain structures (Albert-Gascó et al., 2020). Most of the depositions of amyloid plaques and tau neurofibrillary tangles can be found in the medial temporal lobe and cortex of AD brains (Breijyeh and Karaman, 2020; De Paula et al., 2012; Price and Morris, 1999).

With age being the main risk factor in the development of neurodegenerative diseases (Fjell et al., 2015; Hou et al., 2019), I used 24-month-old (aged) male C57Bl/6NCrI mice in my study. Female mice were not used in the study so to avoid changes in sex hormones not exhibited in male mice (Belaya et al., 2018). The C57Bl/6NCrI aged mice show signs of cognitive decline as early as at 19-20 months of age (www.criver.com). For example, Bialuk et al. used 24-month-old C57BL/6J aged mice with a IL-6-deficiency in their study and found a significant decrease in spatial memory in older mice (Bialuk et al., 2018).

In order to identify Alzheimer's disease, biomarkers are regularly used (Paterson et al., 2014). The most common AD pathology biomarkers in use today are A β 1-42, tau, and p-tau, which correlate to cognitive decline frequently observed in the disease (Blenow et al., 2010; Hou et al., 2019). These markers are obtained from the cerebrospinal fluid and reflect the levels of amyloidosis, neurodegeneration, and tau pathology (Paterson et al., 2014; Wang et al., 2012). Because of its reduced presence in the cerebrospinal fluid of individuals with pathological

Alzheimer's disease, Paterson et al. suggest a new potential CSF biomarker, the TFF3 peptide. Paterson et al. found lower levels of TFF3 to be associated with brain atrophy rates and ventricular expansion, as well as hippocampal atrophy (Paterson et al, 2014). Moreover, in 2014, Tong et al. found the levels of TFF3 in blood, urine, and feces to be useful in the assessment of side effects in the clinical trials of gamma-secretase inhibitors for the treatment of AD (Tong et al., 2012).

The *Tff3* -/- mice were chosen in this study because of their susceptibility to increased levels of neuronal cell death (Liu et al., 2013) and the known role of Tff3 in the normal functioning of the nervous system (Belovari et al., 2015; Bernstein et al., 2015; Gardiner et al., 2013). Additionally, *Tff3* -/- mice have been shown to be prone to decreased mucosal healing (Mashimo et al., 1996), cell apoptosis (Lubka et al., 2009) and impairments of the immune system (Fu et al., 2015).

The hippocampus is one of the brain structures most prominently altered in AD (Lindberg et al., 2012; Moodley and Chan, 2014) and also one of the brain areas where Tff3 can be found (Hinz et al, 2004; Wang et al., 2012). As mentioned in the introduction, the role of Tff3 in the CNS is a new intriguing field, which is why we wanted to analyze the expression of *Bdnf*, *Epac2*, *Egfr*, *L1cam*, and *Nfl* in the hippocampus of *Tff3* -/- mice and Wt controls with the aim to elucidate the possible role of Tff3 in adult neurogenesis, which is reduced in Alzheimer's disease.

Bdnf expression changes in the hippocampus can have a great impact on the state of the organism (Miranda et al., 2019; Autry et al., 2019), especially on cognitive decline in neurodegenerative diseases (Tanila, 2017). Belrose et al. found that postmortem human brains with non-Alzheimer tauopathies have reduced levels of *Bdnf* mRNA (Belrose et al., 2014). Patterson et al. found decreased levels of hippocampal long-term potentiation in mice lacking the *Bdnf* gene (Patterson et al., 1996). Li et al. showed that Tff3 increases the levels of *Bdnf*, pERK1/2, and CREB in the rat hippocampus, and *Bdnf*-ERK-CREB signaling in the hippocampus might be involved in Tff3-mediated antidepressant-like effects (Li et al., 2015). Given that finding, as well as altered *Bdnf* signaling in AD, we wanted to analyze the possible variation of its gene expression in our *Tff3* -/- mice model. The results did not show any significant change in *Bdnf* gene expression concerning Tff3 deficiency. This result could be attributed to the unpredictability of the effect of age on the organism.

It has been demonstrated that deficits of *Egfr* can lead to astrocyte degeneration in the murine cortex (Wagner et al., 2006). Chinery and Playford found that Tff3 and *Egfr* have remedial

synergistic effects on cell migration and gastric damage after Egfr phosphorylation (Chinery and Playford, 1995). Indeed, Tff3 has anti-apoptotic effects, but it can only exert this function through phosphorylating Egfr. This Egfr phosphorylation leads to the inhibition of p53-induced apoptosis (Kinoshita et al., 2000). Egfr activation also leads to the activation of the downstream MAPK/ERK pathway (Baus-Loncar and Giraud, 2005), ultimately leading to cell proliferation, which is one of the anti-neurodegenerative processes (Li et al., 2015). Egfr knockout mice develop neurodegenerative diseases in the first month of their life (Wong and Guillaud, 2004). The majority of Tff3 function studies were done mainly on intestinal epithelial cells and we wanted to analyze if there is an association between Egfr and Tff3 deficiency in the hippocampal tissue which could explain the findings that connect Tff3 and neurodegeneration. However, we did not find any significant difference in Egfr expression in *Tff3*^{-/-} mice compared to Wt mice.

The expression pattern of Epacs is altered in chronic inflammatory diseases in which the cellular microenvironment is changed (Grandoch et al., 2010). Concerning pathological conditions, McPhee and co-workers found low *Epac2* mRNA levels and high *Epac1* mRNA levels in cerebral regions connected to Alzheimer's (McPhee et al., 2005). Defective responses to secondary messengers may bring about these types of disorders (Grandoch et al., 2010). We chose *Epac2* in our study as a potential gene involved in neurogenesis because of the ability of its protein to regulate synaptic plasticity in the CA3 region of the hippocampus (Fernandes et al., 2015) and because Epacs promote neurite outgrowth in the dorsal root ganglia and advance neurite regeneration in the spinal cord (Grandoch et al., 2010). Nevertheless, no significant change was found in *Epac2* expression in *Tff3*^{-/-} mice compared to Wt.

Dysregulation of CAMs can lead to neuropsychiatric disorders (Schmid and Maness, 2008). Mutations in the L1 domain of the L1cam molecule can also cause the so-called L1 syndrome which includes four X-linked conditions: hydrocephalus, corpus callosum hypoplasia, MASA syndrome and spastic paraplegia (Fransen et al., 1997). Dahme et al. carried out a mutation on exon 8 of the *L1* gene and found a reduction in the size of the murine corticospinal tract (Dahme et al., 1997). In our study, however, no significant difference was found in *L1cam* expression in *Tff3*^{-/-} mice.

Nfl gene mutations can lead to a pathologically significant accumulation of neurofilaments, which slow down neuronal transport. These mutations are one of the potential causes of Charcot-Marie-Tooth disease, a neurological disorder characterized by an impairment in the functioning of

Schwann cells of the peripheral nervous system (Gentil et al., 2012). Landau et al. found that increased levels of Nfl in plasma correspond to hypometabolism, future potential atrophy, and the decline of cognitive functions (Landau et al., 2012). Additionally, Mattsson et al. found increased Nfl levels in patients with AD dementia, mild cognitive impairment, preclinical AD, and prodromal AD and therefore concluded that Nfl can be used as a noninvasive biomarker of neurodegeneration in AD (Mattsson et al., 2019). Moreover, Disanto et al. reported that serum Nfl levels were significantly higher in individuals with multiple sclerosis and could therefore be used as relevant biomarkers of the disease (Disanto et al., 2017). Based on these results, we expected increased levels of Nfl in our *Tff3*^{-/-} mice, but no significant difference was observed.

My study's results showed no significant difference in the analyzed genes between aged *Tff3*^{-/-} mice and Wt controls. These results could be negative due to advanced mice age, for our models were 2 years old. The mice's old age might have created a loss of uniformity of physiological changes between the samples. This loss of uniformity could have rendered the animals more prone to having differing expression levels of the genes of interest and therefore lead to unexpected results. Furthermore, the expression levels of *Bdnf*, *Egfr*, *Epac2*, *L1cam* and *Nfl* are all subject to change throughout the lifecycles of both mice and humans. Perhaps it could be interesting to see the expression levels of the same genes in younger mice where the process of adult neurogenesis is more pronounced. Moreover, one strategy could be to experimentally induce neurodegeneration processes (pharmacologically, e.g streptozotocin induction or by nutritional excess, feeding mice high-fat diet) in mice and then to analyze the neurite growth processes and the neurodegenerative status concerning *Tff3*. Indicators of neurodegeneration such as certain behavioral changes could also be investigated. For example, mice could be subjected to learning and spatial memory tests such as the Morris water maze test in which the mice are evaluated on their ability and willingness to exit the maze (Morris, 1984). Nevertheless, it is clear that *Tff3* has a role in the CNS and the development of the brain, and further research is needed to resolve the exact mechanism of its action. *Tff3* could be used to provide new scientific insight and possibly new therapeutic interventions for neurodegenerative diseases.

6. CONCLUSIONS

- The optimal qPCR reaction conditions for the detection and quantification of *Bdnf*, *Egfr*, *Epac2*, *L1cam* and *Nfl* expression in hippocampus of mice were identified.
- There was no significant difference found in the expression levels of *Bdnf*, *Egfr*, *Epac2*, *L1cam* and *Nfl* between the hippocampi of *Tff3*^{-/-} C57Bl6/NCr1 and Wt C57Bl6/NCr1 mice.
- Further research on aged mice with *Tff3* deficiency is warranted.

REFERENCES

- Albert-Gascó, H., Ros-Bernal, F., Castillo-Gómez, E., & Olucha-Bordonau, F. E. (2020). MAP/ERK signaling in developing cognitive and emotional function and its effect on pathological and neurodegenerative processes. *International Journal of Molecular Sciences*, *21*(12), 4471. <https://doi.org/10.3390/ijms21124471>
- Amaral, D. G., Scharfman, H. E., & Lavenex, P. (2007). The dentate gyrus: Fundamental neuroanatomical organization (dentate gyrus for dummies). *The Dentate Gyrus: A Comprehensive Guide to Structure, Function, and Clinical Implications*, 3–790. [https://doi.org/10.1016/s0079-6123\(07\)63001-5](https://doi.org/10.1016/s0079-6123(07)63001-5)
- Arushanyan, É. B., & Beier, É. V. (2008). The hippocampus and cognitive impairments. *Neuroscience and Behavioral Physiology*, *38*(8), 751–758. <https://doi.org/10.1007/s11055-008-9043-0>
- Autry, A. E., & Monteggia, L. M. (2012). Brain-derived neurotrophic factor and neuropsychiatric disorders. *Pharmacological Reviews*, *64*(2), 238–258. <https://doi.org/10.1124/pr.111.005108>
- Baltacı, S. B., Mogulkoc, R., & Baltacı, A. K. (2018). Molecular mechanisms of early and late ltp. *Neurochemical Research*, *44*(2), 281–296. <https://doi.org/10.1007/s11064-018-2695-4>
- Bartsch, T., & Wulff, P. (2015). The hippocampus in aging and disease: from plasticity to vulnerability. *Neuroscience*, *309*, 1–16. <https://doi.org/10.1016/j.neuroscience.2015.07.084>
- Baus-Loncar, M., & Giraud, A. S. (2005). Trefoil factors. *Cellular and Molecular Life Sciences*, *62*(24), 2921–2931. <https://doi.org/10.1007/s00018-005-5480-x>
- Belaya, I., Suwa, M., Chen, T., Giniatullin, R., Kanninen, K. M., Atalay, M., & Kumagai, S. (2018). Long-term exercise protects against cellular stresses in aged mice. *Oxidative Medicine and Cellular Longevity*, *2018*, 1–10. <https://doi.org/10.1155/2018/2894247>
- Belovari, T., Bijelić, N., Tolušić Levak, M., & Baus Lončar, M. (2015). Trefoil factor family peptides tff1 and tff3 in the nervous tissues of developing mouse embryo. *Bosnian Journal of Basic Medical Sciences*, *15*(1). <https://doi.org/10.17305/bjbms.2015.251>
- Belrose, J. C., Masoudi, R., Michalski, B., & Fahnstock, M. (2014). Increased pro-nerve growth factor and decreased brain-derived neurotrophic factor in non-Alzheimer's disease tauopathies. *Neurobiology of Aging*, *35*(4), 926–933. <https://doi.org/10.1016/j.neurobiolaging.2013.08.029>

- Bernstein, H.-G., Dobrowolny, H., Trübner, K., Steiner, J., Bogerts, B., & Hoffmann, W. (2015). Differential regional and cellular distribution of tff3 peptide in the human brain. *Amino Acids*, 47(5), 1053–1063. <https://doi.org/10.1007/s00726-015-1938-9>
- Bialuk, I., Taranta, A., & Winnicka, M. M. (2018). Il-6 deficiency alters spatial memory in 4- and 24-month-old mice. *Neurobiology of Learning and Memory*, 155, 21–29. <https://doi.org/10.1016/j.nlm.2018.06.006>
- Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nature Reviews Neurology*, 6(3), 131–144. <https://doi.org/10.1038/nrneuro.2010.4>
- Bossenmeyer-Pourié Carine, Kannan, R., Ribieras Stéphane, Wendling, C., Stoll, I., Thim, L., Tomasetto, C., & Rio, M.-C. (2002). The trefoil factor 1 participates in Gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. *Journal of Cell Biology*, 157(5), 761–770. <https://doi.org/10.1083/jcb200108056>
- Brejijeh, Z., & Karaman, R. (2020). Comprehensive review on alzheimer’s disease: causes and treatment. *Molecules*, 25(24), 5789. <https://doi.org/10.3390/molecules25245789>
- Chinery, R., & Playford, R. J. (1995). Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indomethacin-induced gastric damage in the rat. *Clinical Science*, 88(4), 401–403. <https://doi.org/10.1042/cs0880401>
- Clelland, C. D., Choi, M., Romberg, C., Clemenson, G. D., Fagniere, A., Tyers, P., Jessberger, S., Saksida, L. M., Barker, R. A., Gage, F. H., & Bussey, T. J. (2009). A functional role for adult hippocampal neurogenesis in spatial pattern separation. *Science*, 325(5937), 210–213. <https://doi.org/10.1126/science.1173215>
- Cook, G. A., Familiarì, M., Thim, L., & Giraud, A. S. (1999). The trefoil peptides TFF2 and tff3 are expressed in rat lymphoid tissues and participate in the immune response. *FEBS Letters*, 456(1), 155–159. [https://doi.org/10.1016/s0014-5793\(99\)00940-0](https://doi.org/10.1016/s0014-5793(99)00940-0)
- Dahme, M., Bartsch, U., Martini, R., Anliker, B., Schachner, M., & Mantei, N. (1997). Disruption of the mouse Il gene leads to malformations of the nervous system. *Nature Genetics*, 17(3), 346–349. <https://doi.org/10.1038/ng1197-346>
- De-Paula, V. J., Radanovic, M., Diniz, B. S., & Forlenza, O. V. (2012). Alzheimer’s disease. *Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease*, 329–352. https://doi.org/10.1007/978-94-007-5416-4_14
- Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., Kappos, L., Gobbi, C., & Kuhle, J. (2017). Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. *Annals of Neurology*, 81(6), 857–870. <https://doi.org/10.1002/ana.24954>

- Fernandes, H. B., Riordan, S., Nomura, T., Remmers, C. L., Kraniotis, S., Marshall, J. J., Kukreja, L., Vassar, R., & Contractor, A. (2015). Epac2 mediates camp-dependent potentiation of neurotransmission in the hippocampus. *Journal of Neuroscience*, *35*(16), 6544–6553. <https://doi.org/10.1523/jneurosci.0314-14.2015>
- Fjell, A. M., McEvoy, L., Holland, D., Dale, A. M., & Walhovd, K. B. (2014). What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. *Progress in Neurobiology*, *117*, 20–40. <https://doi.org/10.1016/j.pneurobio.2014.02.004>
- Fransen, E. (1997). L1-associated diseases: clinical geneticists divide, molecular geneticists unite. *Human Molecular Genetics*, *6*(10), 1625–1632. <https://doi.org/10.1093/hmg/6.10.1625>
- Fu, T., Stellmacher, A., Znalesniak, E. B., Dieterich, D. C., Kalbacher, H., & Hoffmann, W. (2014). Tff3 is expressed in neurons and microglial cells. *Cellular Physiology and Biochemistry*, *34*(6), 1912–1919. <https://doi.org/10.1159/000366389>
- Fu, T., Znalesniak, E. B., Kalinski, T., Möhle, L., Biswas, A., Salm, F., Dunay, I. R., & Hoffmann, W. (2015). Tff peptides play a role in the immune response following oral infection of mice with *Toxoplasma Gondii*. *European Journal of Microbiology and Immunology*, *5*(3), 221–231. <https://doi.org/10.1556/1886.2015.00028>
- Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., & Zetterberg, H. (2019). Neurofilament light chain as a biomarker in neurological disorders. *Journal of Neurology, Neurosurgery & Psychiatry*, *90*(8), 870–881. <https://doi.org/10.1136/jnnp-2018-320106>
- Gardiner, E. J., Cairns, M. J., Liu, B., Beveridge, N. J., Carr, V., Kelly, B., Scott, R. J., & Tooney, P. A. (2013). Gene expression analysis reveals schizophrenia-associated dysregulation of immune pathways in peripheral blood mononuclear cells. *Journal of Psychiatric Research*, *47*(4), 425–437. <https://doi.org/10.1016/j.jpsychires.2012.11.007>
- Gentil, B. J., & Cooper, L. (2012). Molecular basis of axonal dysfunction and traffic impairments in CMT. *Brain Research Bulletin*, *88*(5), 444–453. <https://doi.org/10.1016/j.brainresbull.2012.05.003>
- Gonçalves, J. T., Schafer, S. T., & Gage, F. H. (2016). Adult neurogenesis in the hippocampus: from stem cells to behavior. *Cell*, *167*(4), 897–914. <https://doi.org/10.1016/j.cell.2016.10.021>
- Gött, P., Beck, S., Machado, J. C., Carneiro, F., Schmitt, H., & Blin, N. (1996). Human trefoil peptides: genomic structure in 21q22.3 and coordinated expression. *European Journal of Human Genetics*, *4*(6), 308–315. <https://doi.org/10.1159/000472224>

- Grandoch, M., Roscioni, S. S., & Schmidt, M. (2009). The role of EPAC proteins, novel camp mediators, in the regulation of immune, lung and neuronal function. *British Journal of Pharmacology*, *159*(2), 265–284. <https://doi.org/10.1111/j.1476-5381.2009.00458.x>
- Griepentrog, T., Bauer, M., Hornstein, C., Sauer, H., & Jirikowski, G. (2000). Coexistence of intestinal trefoil factor (HITF) and oxytocin in magnocellular neurons in the human hypothalamus. *Hormone and Metabolic Research*, *32*(04), 121–124. <https://doi.org/10.1055/s-2007-978604>
- Gulyaeva, N. V. (2017). Molecular mechanisms of neuroplasticity: an expanding universe. *Biochemistry (Moscow)*, *82*(3), 237–242. <https://doi.org/10.1134/s0006297917030014>
- Hampel, H., O'Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018). Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. *Nature Reviews Neurology*, *14*(11), 639–652. <https://doi.org/10.1038/s41582-018-0079-7>
- Hinz, M., Schwegler, H., Chwieralski, C. E., Laube, G., Linke, R., Pohle, W., & Hoffmann, W. (2004). Trefoil factor Family (TFF) expression in the mouse brain and pituitary: changes in the developing cerebellum. *Peptides*, *25*(5), 827–832. <https://doi.org/10.1016/j.peptides.2004.01.020>
- Hoffmann, Werner, W. Jagla, and A. Wiede. "Molecular medicine of TFF-peptides: from gut to brain." *Histology and histopathology* 16.1 (2001): 319-334. <https://doi.org/10.14670/hh-16.319>
- Hoffmann, W., & Jagla, W. (2002). Cell type specific expression of secretory Tff peptides: colocalization with mucins and synthesis in the brain. *International Review of Cytology*. [https://doi.org/10.1016/s0074-7696\(02\)13014-2](https://doi.org/10.1016/s0074-7696(02)13014-2)
- Hortsch, M. (1996). The L1 family of neural cell adhesion molecules: old proteins performing new tricks. *Neuron*, *17*(4), 587–593. [https://doi.org/10.1016/s0896-6273\(00\)80192-0](https://doi.org/10.1016/s0896-6273(00)80192-0)
- Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019). Ageing as a risk factor for neurodegenerative disease. *Nature Reviews Neurology*, *15*(10), 565–581. <https://doi.org/10.1038/s41582-019-0244-7>
- Hu, C., Hu, J., Meng, X., Zhang, H., Shen, H., Huang, P., Schachner, M., & Zhao, W. (2020). L1CAM beneficially inhibits histone deacetylase 2 expression under conditions of Alzheimer's Disease. *Current Alzheimer Research*, *17*(4), 382–392. <https://doi.org/10.2174/1567205017666200422155323>
- Jagla, W., Wiede, A., Dietzmann, K., Rutkowski, K., & Hoffmann, W. (2000). Co-localization of TFF3 peptide and oxytocin in the human hypothalamus. *The FASEB Journal*, *14*(9), 1126–1131. <https://doi.org/10.1096/fasebj.14.9.1126>

- Jones, K. A., Sumiya, M., Woolfrey, K. M., Srivastava, D. P., & Penzes, P. (2019). Loss of epac2 alters dendritic spine morphology and inhibitory synapse density. *Molecular and Cellular Neuroscience*, *98*, 19–31. <https://doi.org/10.1016/j.mcn.2019.05.001>
- Jurk, D., Wang, C., Miwa, S., Maddick, M., Korolchuk, V., Tsolou, A., Gonos, E. S., Thrasivoulou, C., Jill Saffrey, M., Cameron, K., & von Zglinicki, T. (2012). Postmitotic neurons develop a p21-dependent senescence-like phenotype driven by a DNA damage response. *Aging Cell*, *11*(6), 996–1004. <https://doi.org/10.1111/j.1474-9726.2012.00870.x>
- Kinoshita, K., Taupin, D. R., Itoh, H., & Podolsky, D. K. (2000). Distinct pathways of cell migration and antiapoptotic response to epithelial injury: structure-function analysis of human intestinal trefoil factor. *Molecular and Cellular Biology*, *20*(13), 4680–4690. <https://doi.org/10.1128/mcb.20.13.4680-4690.2000>
- Kopcewicz, M., Walendzik, K., Bukowska, J., Kur-Piotrowska, A., Machcinska, S., Gimble, J. M., & Gawronska-Kozak, B. (2020). Cutaneous wound healing in aged, high fat diet-induced obese female or male c57bl/6 mice. *Aging*, *12*(8), 7066–7111. <https://doi.org/10.18632/aging.103064>
- Landau, S. M., Mintun, M. A., Joshi, A. D., Koeppe, R. A., Petersen, R. C., Aisen, P. S., Weiner, M. W., & Jagust, W. J. (2012). Amyloid deposition, hypometabolism, and longitudinal cognitive decline. *Annals of Neurology*, *72*(4), 578–586. <https://doi.org/10.1002/ana.23650>
- Leal, G., Bramham, C. R., & Duarte, C. B. (2017). BDNF and hippocampal synaptic plasticity. *Vitamins and Hormones*, 153–195. <https://doi.org/10.1016/bs.vh.2016.10.004>
- Lefebvre, O., Chenard, M.-P., Masson, R., Linares, J., Dierich, A., LeMeur, M., Wendling, C., Tomasetto, C., Chambon, P., & Rio, M.-C. (1996). Gastric mucosa abnormalities and tumorigenesis in mice lacking the ps2 trefoil protein. *Science*, *274*(5285), 259–262. <https://doi.org/10.1126/science.274.5285.259>
- Leuner, B., & Gould, E. (2010). Structural plasticity and hippocampal function. *Annual Review of Psychology*, *61*(1), 111–140. <https://doi.org/10.1146/annurev.psych.093008.100359>
- Lindberg, O., Walterfang, M., Looi, J. C. L., Malykhin, N., Östberg, P., Zandbelt, B., Styner, M., Paniagua, B., Velakoulis, D., Örndahl, E., & Wahlund, L.-O. (2012). Shape analysis of the hippocampus in alzheimer's disease and subtypes of frontotemporal lobar degeneration. *Journal of Alzheimer's Disease*, *30*(2), 355–365. <https://doi.org/10.3233/jad-2012-112210>
- Li, J., Luo, Y., Zhang, R., Shi, H., Zhu, W., & Shi, J. (2015). Neuropeptide trefoil factor 3 reverses depressive-like behaviors by activation of BDNF-ERK-CREB signaling in olfactory bulbectomized rats. *International Journal of Molecular Sciences*, *16*(12), 28386–28400. <https://doi.org/10.3390/ijms161226105>

- Liu, S. Q., Roberts, D., Zhang, B., Ren, Y., Zhang, L.-Q., & Wu, Y. H. (2013). Trefoil factor 3 as an endocrine neuroprotective factor from the liver in experimental cerebral ischemia/reperfusion injury. *PLoS ONE*, *8*(10). <https://doi.org/10.1371/journal.pone.0077732>
- Lubka, M., Shah, A. A., Blin, N., & Baus-Lončar, M. (2009). The intestinal trefoil factor (tff3), also expressed in the inner ear, interacts with peptides contributing to apoptosis. *Journal of Applied Genetics*, *50*(2), 167–171. <https://doi.org/10.1007/bf03195669>
- May, F. E., & Westley, B. R. (1997). Trefoil proteins: their role in normal and malignant cells. *The Journal of Pathology*, *183*(1), 4–7. [https://doi.org/10.1002/\(sici\)1096-9896\(199709\)183:1<4::aid-path1099>3.0.co;2-5](https://doi.org/10.1002/(sici)1096-9896(199709)183:1<4::aid-path1099>3.0.co;2-5)
- Mashimo, H., Wu, D.-C., Podolsky, D. K., & Fishman, M. C. (1996). Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. *Science*, *274*(5285), 262–265. <https://doi.org/10.1126/science.274.5285.262>
- Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H., & Blennow, K. (2019). Association between longitudinal plasma neurofilament light and neurodegeneration in patients with alzheimer disease. *JAMA Neurology*, *76*(7), 791. <https://doi.org/10.1001/jamaneurol.2019.0765>
- Miranda, M., Morici, J. F., Zanoni, M. B., & Bekinschtein, P. (2019). Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. *Frontiers in Cellular Neuroscience*, *13*. <https://doi.org/10.3389/fncel.2019.00363>
- Moodley, K. K., & Chan, D. (2014). The hippocampus in neurodegenerative disease. *Frontiers of Neurology and Neuroscience*, 95–108. <https://doi.org/10.1159/000356430>
- Moreno-Jiménez, E. P., Flor-García, M., Terreros-Roncal, J., Rábano, A., Cafini, F., Pallas-Bazarra, N., Ávila, J., & Llorens-Martín, M. (2019). Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer's disease. *Nature Medicine*, *25*(4), 554–560. <https://doi.org/10.1038/s41591-019-0375-9>
- Morris, R. (1984). Developments of a water-maze procedure for studying spatial learning in the rat. *Journal of Neuroscience Methods*, *11*(1), 47–60. [https://doi.org/10.1016/0165-0270\(84\)90007-4](https://doi.org/10.1016/0165-0270(84)90007-4)
- Moser, M.-B., & Moser, E. I. (1998). Functional differentiation in the hippocampus. *Hippocampus*, *8*(6), 608–619. [https://doi.org/10.1002/\(sici\)1098-1063\(1998\)8:6<608::aid-hipo3>3.0.co;2-7](https://doi.org/10.1002/(sici)1098-1063(1998)8:6<608::aid-hipo3>3.0.co;2-7)
- Murray, A. J., & Shewan, D. A. (2008). Epac mediates cyclic AMP-dependent axon growth, guidance and regeneration. *Molecular and Cellular Neuroscience*, *38*(4), 578–588. <https://doi.org/10.1016/j.mcn.2008.05.006>

- Nicoll, R. A. (2017). A brief history of long-term potentiation. *Neuron*, *93*(2), 281–290. <https://doi.org/10.1016/j.neuron.2016.12.015>
- Paterson, R. W., Bartlett, J. W., Blennow, K., Fox, N. C., Shaw, L. M., Trojanowski, J. Q., Zetterberg, H., & Schott, J. M. (2014). Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. *Translational Psychiatry*, *4*(7). <https://doi.org/10.1038/tp.2014.58>
- Patterson, S. L., Abel, T., Deuel, T. A. S., Martin, K. C., Rose, J. C., & Kandel, E. R. (1996). Recombinant bdnf rescues deficits in basal synaptic transmission and hippocampal ltp in bdnf knockout mice. *Neuron*, *16*(6), 1137–1145. [https://doi.org/10.1016/s0896-6273\(00\)80140-3](https://doi.org/10.1016/s0896-6273(00)80140-3)
- Podolsky, D. K., Lynch-Devaney, K., Stow, J. L., Oates, P., Murgue, B., DeBeaumont, M., Sands, B. E., & Mahida, Y. R. (1993). Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. *Journal of Biological Chemistry*, *268*(9), 6694–6702. [https://doi.org/10.1016/s0021-9258\(18\)53305-6](https://doi.org/10.1016/s0021-9258(18)53305-6)
- Podolsky, D. K. (1997). Healing the epithelium: solving the problem from two sides. *Journal of Gastroenterology*, *32*(1), 122–126. <https://doi.org/10.1007/bf01213309>
- Price, J. L., & Morris, J. C. (1999). Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. *Annals of Neurology*, *45*(3), 358–368. [https://doi.org/10.1002/1531-8249\(199903\)45:3<358::aid-ana12>3.0.co;2-x](https://doi.org/10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x)
- Probst, J. C., Skutella, T., Müller-Schmid, A., Jirikowski, G. F., & Hoffmann, W. (1995). Molecular and cellular analysis of rP1. B in the rat hypothalamus: in situ hybridization and immunohistochemistry of a new P-domain neuropeptide. *Molecular Brain Research*, *33*(2), 269–276. [https://doi.org/10.1016/0169-328x\(95\)00137-h](https://doi.org/10.1016/0169-328x(95)00137-h)
- Probst, J. C., Zetzsche, T., Weber, M., Theilemann, P., Skutella, T., Landgraf, R., & Jirikowski, G. F. (1996). Human intestinal trefoil factor is expressed in human hypothalamus and pituitary: evidence for a novel neuropeptide. *The FASEB Journal*, *10*(13), 1518–1523. <https://doi.org/10.1096/fasebj.10.13.8940297>
- Schmid, R. S., & Maness, P. F. (2008). L1 and NCAM adhesion molecules as signaling coreceptors in neuronal migration and process outgrowth. *Current Opinion in Neurobiology*, *18*(3), 245–250. <https://doi.org/10.1016/j.conb.2008.07.015>
- Schultz, C., & Engelhardt, M. (2014). Anatomy of the hippocampal formation. *Frontiers of Neurology and Neuroscience*, 6–17. <https://doi.org/10.1159/000360925>
- Schwarzberg, H., Kalbacher, H., & Hoffmann, W. (1999). Differential behavioral effects of TFF peptides: injections of synthetic TFF3 into the rat amygdala. *Pharmacology Biochemistry and Behavior*, *62*(1), 173–178. [https://doi.org/10.1016/s0091-3057\(98\)00137-3](https://doi.org/10.1016/s0091-3057(98)00137-3)

- Scoville, W. B., & Milner, B. (1957). Loss of recent memory after bilateral hippocampal lesions. *Journal of Neurology, Neurosurgery & Psychiatry*, *20*(1), 11–21. <https://doi.org/10.1136/jnnp.20.1.11>
- Sekido, K., Tomihara, K., Tachinami, H., Heshiki, W., Sakurai, K., Moniruzzaman, R., Imaue, S., Fujiwara, K., & Noguchi, M. (2019). Alterations in composition of immune cells and impairment of anti-tumor immune response in aged oral cancer-bearing mice. *Oral Oncology*, *99*, 104462. <https://doi.org/10.1016/j.oraloncology.2019.104462>
- Shi, H.-S., Zhu, W.-L., Liu, J.-F., Luo, Y.-X., Si, J.-J., Wang, S.-J., Xue, Y.-X., Ding, Z.-B., Shi, J., & Lu, L. (2012). PI3K/Akt signaling pathway in the basolateral amygdala mediates the rapid antidepressant-like effects of trefoil factor 3. *Neuropsychopharmacology*, *37*(12), 2671–2683. <https://doi.org/10.1038/npp.2012.131>
- Spalding, K. L., Bergmann, O., Alkass, K., Bernard, S., Salehpour, M., Huttner, H. B., Boström, E., Westerlund, I., Vial, C., Buchholz, B. A., Possnert, G., Mash, D. C., Druid, H., & Frisén, J. (2013). Dynamics of hippocampal neurogenesis in adult humans. *Cell*, *153*(6), 1219–1227. <https://doi.org/10.1016/j.cell.2013.05.002>
- Ribieras, S., Tomasetto, C., & Rio, M.-C. (1998). The ps2/tff1 trefoil factor, from basic research to clinical applications. *Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer*, *1378*(1). [https://doi.org/10.1016/s0304-419x\(98\)00016-x](https://doi.org/10.1016/s0304-419x(98)00016-x)
- Tanila, H. (2017). The role of BDNF in Alzheimer's disease. *Neurobiology of Disease*, *97*, 114–118. <https://doi.org/10.1016/j.nbd.2016.05.008>
- Tavassoly, O., Sato, T., & Tavassoly, I. (2020). Inhibition of brain epidermal growth factor receptor activation: a novel target in neurodegenerative diseases and brain injuries. *Molecular Pharmacology*, *98*(1), 13–22. <https://doi.org/10.1124/mol.120.119909>
- Thim, L. (1989). A new family of growth factor-like peptides ‘Trefoil’ disulphide loop structures as a common feature in breast cancer associated peptide (pS2), pancreatic spasmodic polypeptide (PSP), and frog skin peptides (spasmolysins). *FEBS Letters*, *250*(1), 85–90. [https://doi.org/10.1016/0014-5793\(89\)80690-8](https://doi.org/10.1016/0014-5793(89)80690-8)
- Thim, L. (1994). Trefoil peptides: a new family of gastrointestinal molecules. *Digestion*, *55*(6), 353–360. <https://doi.org/10.1159/000201165>
- Thim, L. (1997). Trefoil peptides: from structure to function. *Cellular and Molecular Life Sciences*, *53*(12), 888. <https://doi.org/10.1007/s000180050108>

- Tong, G., Wang, J.-S., Sverdlov, O., Huang, S.-P., Slemmon, R., Croop, R., Castaneda, L., Gu, H., Wong, O., Li, H., Berman, R. M., Smith, C., Albright, C. F., & Dockens, R. C. (2012). Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ -secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. *Clinical Therapeutics*, *34*(3), 654–667. <https://doi.org/10.1016/j.clinthera.2012.01.022>
- Tropepe, V., Sibilina, M., Ciruna, B. G., Rossant, J., Wagner, E. F., & van der Kooy, D. (1999). Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. *Developmental Biology*, *208*(1), 166–188. <https://doi.org/10.1006/dbio.1998.9192>
- Wagner, B., Natarajan, A., Grönaug, S., Kroismayr, R., Wagner, E. F., & Sibilina, M. (2006). Neuronal survival depends on EGFR signaling in cortical but not midbrain astrocytes. *The EMBO Journal*, *25*(4), 752–762. <https://doi.org/10.1038/sj.emboj.7600988>
- Wang, L., Chiang, H.-C., Wu, W., Liang, B., Xie, Z., Yao, X., Ma, W., Du, S., & Zhong, Y. (2012). Epidermal growth factor receptor is a preferred target for treating amyloid-induced memory loss. *Proceedings of the National Academy of Sciences*, *109*(41), 16743–16748. <https://doi.org/10.1073/pnas.1208011109>
- Wang, L., Fagan, A. M., Shah, A. R., Beg, M. F., Csernansky, J. G., Morris, J. C., & Holtzman, D. M. (2012). Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type. *Alzheimer Disease & Associated Disorders*, *26*(4), 314–321. <https://doi.org/10.1097/wad.0b013e31823c0cf4>
- Wong, R. W., & Guillaud, L. (2004). The role of epidermal growth factor and its receptors in mammalian CNS. *Cytokine & Growth Factor Reviews*, *15*(2-3), 147–156. <https://doi.org/10.1016/j.cytogfr.2004.01.004>
- Yamada, M., Ikeuchi, T., & Hatanaka, H. (1997). The neurotrophic action and signalling of epidermal growth factor. *Progress in Neurobiology*, *51*(1), 19–37. [https://doi.org/10.1016/s0301-0082\(96\)00046-9](https://doi.org/10.1016/s0301-0082(96)00046-9)
- Zou, J., Chen, Z., Liang, C., Fu, Y., Wei, X., Lu, J., Pan, M., Guo, Y., Liao, X., Xie, H., Wu, D., Li, M., Liang, L., Wang, P., & Wang, Q. (2018). Trefoil factor 3, cholinesterase and homocysteine: potential predictors for Parkinson's disease dementia and vascular parkinsonism dementia in advanced stage. *Aging and Disease*, *9*(1), 51. <https://doi.org/10.14336/ad.2017.0416>
- www.criver.com/products-services/discovery-services/pharmacology-studies/neuroscience-models-assays/alzheimers-disease-studies/aged-rats-and-mice-cognitive-decline?region=3696 (accessed on 9/8/2021)
- www.gene-quantification.de/SIAL-qPCR-Technical-Guide.pdf (accessed on 10/7/2021)
- www.thermofisher.com (accessed on 13/6/2021)

Curriculum Vitae

Born in 1996 in Zagreb (Croatia), I attended the 16th Gymnasium (High school with Extended Languages Curriculum). My tertiary education began in 2015 when I enrolled in the undergraduate program of Molecular biology at the Faculty of Science of the University of Zagreb. I obtained my Bachelor's degree in 2018 and the same year enrolled in the graduate program of Molecular biology. My first internship was conducted in the Laboratory of Plant Physiology at my faculty (under the mentorship of Željka Vidaković Cifrek, PhD, Prof). Besides my studies in Croatia, I also studied outside of my home country. During the summer of 2018, I did an Erasmus internship in the Laboratory of Molecular Bacteriology at the Medical University of Gdansk in Poland. As an Erasmus student in Spain in the summer semester of 2019, I was enrolled in biotechnological courses at the Technical University of Madrid.

There were a couple of projects which I volunteered on at my faculty: “Barcode of Life” (topic of molecular ecology under the mentorship of Lucija Šerić Jelaska, PhD) and research on the *Pontastacus leptodactylus* genome (topic of cytogenetics under the mentorship of Višnja Besendorfer, PhD, Prof), with the latter published as a scientific paper. Additionally, in June this year (2021) I was a student intern in Pliva (Teva) in the marketing and sales sector. Except from the accomplishments at my faculty, my academic development included acquiring foreign language speaking skills. During my education, I obtained a C1 IELTS certificate (English), a B2 DELE certificate (Spanish), and a B2 DELF certificate (French). Moreover, in the summer of 2020 I was awarded a scholarship by the French Government to spend a month in France studying French language and culture.

PUBLICATIONS:

Mlinarec, Jelena, et al. “The *Pontastacus leptodactylus* (Astacidae) repeatome provides insight into genome evolution and reveals a remarkable diversity of satellite DNA.” *Frontiers in Genetics* 11 (2020): 1820.

email: lanusic@stud.biol.pmf.hr